Skip to content

Study · Not a test of the peptide alone · 2015

4 results

Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy.

Kapitza C, Bode B, Ingwersen SH, Jacobsen LV, Poulsen P

Journal of clinical pharmacology14 Jul 2015Cited by 23 (Europe PMC)

PMID25998481 (opens in a new tab)DOI10.1002/jcph.549 (opens in a new tab)PepBankPUB-25998481
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneRandomized controlled trialPharmacokinetics

    In a crossover study in healthy subjects, the pharmacokinetic properties of insulin degludec and liraglutide were preserved when given as the fixed-ratio combination IDegLira.

    In plain wordsIn healthy people, the combination product gave insulin degludec and liraglutide blood levels similar to those of the separate drugs.

    Peptide
    Liraglutide
    Outcome
    Not applicablePreservation of pharmacokinetic properties in IDegLira
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Overall, the PK properties of IDeg and liraglutide were preserved for IDegLira.
    1 context sentence
    Summary · context
    A single-dose, randomized, 4-period crossover clinical pharmacology study in healthy subjects compared the bioavailability of IDegLira with its monocomponents.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneRandomized controlled trialPharmacokinetics

    In a crossover study in healthy subjects, liraglutide exposure was lower when dosed as IDegLira than as the monocomponent, but met the criterion for equivalence.

    In plain wordsIn healthy people, liraglutide blood levels were lower in the combination product than with liraglutide alone, but were within the equivalence limit.

    Peptide
    Liraglutide
    Outcome
    Not applicableLiraglutide exposure in IDegLira, bioequivalence
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Liraglutide exposure was lower when dosed as IDegLira but met the criterion for equivalence.
    1 context sentence
    Summary · context
    A single-dose, randomized, 4-period crossover clinical pharmacology study in healthy subjects compared the bioavailability of IDegLira with its monocomponents.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneRandomized controlled trialPharmacokinetics

    In adults with type 2 diabetes, no relevant deviations from dose proportionality were observed for the IDegLira components.

    In plain wordsIn adults with type 2 diabetes, drug levels in the combination product rose in proportion to the dose.

    Peptide
    Liraglutide
    Outcome
    No significant changeDose proportionality of IDegLira components
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    No relevant deviations from dose proportionality for the IDegLira components were observed.
    1 context sentence
    Summary · context
    Dose proportionality, covariate effects on exposure, and exposure-response for change in glycated hemoglobin were analyzed based on data from a randomized treat-to-target phase 3 study in subjects with type 2 diabetes.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the glycemic response to IDegLira was larger than with insulin degludec or liraglutide alone across the dose and exposure range.

    In plain wordsIn adults with type 2 diabetes, the combination product lowered blood sugar more than insulin degludec or liraglutide alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseGlycemic response (HbA1c change), IDegLira vs components
    Study

    n: not reported in source

    Comparator
    Insulin degludec or liraglutide alone (pooled)
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Glycemic response to IDegLira was larger than with IDeg or liraglutide alone, reflecting their distinct glucose-lowering effects throughout the dose/exposure range.
    1 context sentence
    Summary · context
    Dose proportionality, covariate effects on exposure, and exposure-response for change in glycated hemoglobin were analyzed based on data from a randomized treat-to-target phase 3 study in subjects with type 2 diabetes.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01336023

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 1,66323 May 2011 to 22 Nov 2012

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 19 Feb 2018
CompletedPhase 1NCT00983021

Safety and Tolerability of NN9068 in Healthy Male Volunteers

Novo Nordisk A/Sn = 24Sept 2009 to Dec 2009

Diabetes · Healthy

Trial pageClinicalTrials.govUpdated 8 Feb 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.